Volume 20, Number 6—June 2014
Letter
Distinguishing Nontuberculous Mycobacteria from Multidrug-Resistant Mycobacterium tuberculosis, China
Kaijin Xu, Sheng Bi, Zhongkang Ji, Haiyang Hu, Feisu Hu, Beiwen Zheng, Bing Wang, Jingjing Ren, Shigui Yang, Min Deng, Ping Chen, Bing Ruan, Jifang Sheng, and Lanjuan Li
Table
Gene mutations of 214 drug-resistant tubercle bacilli, Zhejiang Province, China, 2011–2012
| Drug |
Mutant points |
Mutant times | ||
|---|---|---|---|---|
| Mutant times for single site, no. (%)* |
Total no. mutant times of sites related to drug resistance |
|||
| Isoniazid | inhA-15 (C→T) | 32 (18.6) | 172† | |
| katG315 (G→C), (G→A) |
140 (81.4) |
|||
| Rifampin | rpoB511 (T→C) | 10 (7.1) | 140‡ | |
| rpoB513 (A→C) | 2 (1.4) | |||
| rpoB516 (A→T), (A→G), (G→T) | 19 (13.6) | |||
| rpoB526 (A→G), (A→T), (C→G), (C→T) | 21 (15) | |||
| rpoB531 (C→G), (C→T) | 84 (60.0) | |||
| rpoB533 (T→C) | 4 (2.9) | |||
*No. mutant times for single site/total no. mutant times of sites related to drug resistance.
†A strain simultaneously had katG315 (G→C) and inhA-15 (C→T).
‡Five strains had the double mutation of rpoB.
Page created: May 19, 2014
Page updated: May 19, 2014
Page reviewed: May 19, 2014
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.